Test environment running 7.6.6

Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Evaluating medicines: let's use all the evidence

Thumbnail Image

Date

2007

Authors

Kelman, Chris
Pearson, Sallie-Anne
Day, Richard O
Holman, C. D'Arcy J.
Kliewer, Erich V
Henry, David A

Journal Title

Journal ISSN

Volume Title

Publisher

Australasian Medical Association

Abstract

• The current drug regulatory system is outdated and relies primarily on a process of premarketing evaluation, followed by periodic reviews of reported adverse events. • While long-term medicine use for chronic conditions is now commonplace, current d

Description

Keywords

Keywords: diclofenac; leflunomide; methotrexate; rofecoxib; thalidomide; Australia; birth defect; clinical practice; clinical research; drug approval; drug control; drug efficacy; drug marketing; drug monitoring; drug safety; drug surveillance program; evidence bas

Citation

URI

http://hdl.handle.net/1885/36161

Collections

Open Access Research

Source

Medical Journal of Australia

Type

Journal article

Book Title

Entity type

Access Statement

License Rights

DOI

Restricted until

2037-12-31

Downloads

File
Description
01_Kelman_Evaluating_medicines:_let's_2007.pdf (233.71 KB)

DSpace software copyright © 2002-2026 LYRASIS